Literature DB >> 27574179

Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation.

Hassan A Aziz1, Yahya A Al Zahrani1, James Bena2, Brandy Lorek1, Allan Wilkinson3, John Suh3, Arun D Singh1.   

Abstract

PURPOSE: To compare the rates of tumour recurrence following episcleral brachytherapy for uveal melanoma before and after implementation of intraoperative echographic confirmation of plaque placement.
MATERIALS AND METHODS: All patients with primary single ciliary body or choroidal melanoma treated with iodine-125 or ruthenium-106 plaque brachytherapy between 1 January 2004 and 30 December 2013 were included. Exclusion criteria were patients with previous radiation treatment and patients who received adjuvant transpupillary thermotherapy. Since February 2007, intraoperative echographic confirmation was initiated to ensure that the plaque was centred on the tumour base and/or all tumour margins were covered by the plaque.
RESULTS: 252 patients were included in the study. Local tumour control after primary brachytherapy was achieved in 242/252 (96.0%). Of the 10 patients with treatment failure, 8 patients had local recurrence and 2 patients had failure to response. With the incorporation of the intraoperative echographic confirmation for plaque positioning the treatment failure rate decreased from 9.3% (5/54 patients) to 1.5% (3/198 patients). Continuous and categorical univariable predictors of recurrence were analysed for statistical significance. The only statistically significant variable was the intraoperative echographic confirmation (HR: 0.16; p=0.032) for recurrence within the first 24 months.
CONCLUSIONS: Intraoperative echographic confirmation of plaque placement during episcleral brachytherapy for choroidal melanoma reduces the risk of early local recurrence. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Choroid; Diagnostic tests/Investigation; Retina

Mesh:

Year:  2016        PMID: 27574179     DOI: 10.1136/bjophthalmol-2016-309153

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

1.  Choroidal Melanoma with Ultrasound-Guided Episcleral Brachytherapy: Long-Term Results and Risk of Metastasis.

Authors:  Beatriz Quiles; Jorge Mataix; José Luis Guinot; Isabel Wang; Victor De Los Dolores; Marina Peña; Alonso La Rosa; Maribel Tortajada; Miguel Santos; Leoncio Arribas
Journal:  Ocul Oncol Pathol       Date:  2021-05-05

Review 2.  Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.

Authors:  Jose J Echegaray; Nikolaos E Bechrakis; Nakul Singh; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-08

3.  Histopathologic Patterns of Recurrent Choroidal Melanoma Following I-125 Plaque Brachytherapy.

Authors:  Jose J Echegaray; Thomas Plesec; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2019-06-18

4.  Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques.

Authors:  Andrew J Wong; Bin S Teh; Brandon T Nguyen; Ramiro Pino; Maria E Bretana; Eric H Bernicker; Patricia Chevez-Barrios; E Brian Butler; Amy C Schefler
Journal:  J Contemp Brachytherapy       Date:  2022-04-11

Review 5.  Recent advancements in the management of retinoblastoma and uveal melanoma.

Authors:  Amy C Schefler; Ryan S Kim
Journal:  F1000Res       Date:  2018-04-18

6.  Temporal Relationship Between Visual Field, Retinal and Microvascular Pathology Following 125I-Plaque Brachytherapy for Uveal Melanoma.

Authors:  Michelle R Tamplin; Wenxiang Deng; Mona K Garvin; Elaine M Binkley; Daniel E Hyer; John M Buatti; Johannes Ledolter; H Culver Boldt; Randy H Kardon; Isabella M Grumbach
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.